Hims & Hers Health will acquire Boston-based YourBio Health, a microneedle blood sampling firm.
YourBio’s TAP device uses bladeless microneedles to collect capillary blood in seconds with minimal discomfort. Microneedles are tiny, short needles that draw small samples without a full venous draw.
The transaction is expected to close in early 2026, subject to customary regulatory approvals and closing conditions. The deal will be funded entirely in cash from Hims & Hers’ balance sheet; the value was not disclosed.
Andrew Dudum, founder and chief executive of Hims & Hers, said: “The next generation of health innovation will be built on proprietary technologies that make wellness simpler, more comfortable, and more human.
“YourBio’s patented TAP and HALO technologies represent major advancements in user experience and design, and we’re excited to bring them into the Hims & Hers ecosystem.”
Dr Michael Mina, chief scientific officer at YourBio Health, said: “YourBio’s HALO and TAP technologies are ushering in some of the most significant scientific advancements in the blood collection space in decades.
“By using micro-needles thinner than an eyelash, these systems produce high-quality blood samples with essentially no discomfort. This technology has the potential to change how people engage with routine blood collection – replacing long waits and painful needles with a far more convenient, user-friendly experience.
Paul Owen, chief executive of YourBio Health, said: “For decades, blood sampling has remained largely unchanged – forcing patients and healthcare providers through an inefficient process that causes pain and discomfort, heightens anxieties, and often takes more blood than is necessary.
“By rethinking every aspect of the experience – from comfort and design to accessibility – we’re reimagining what the modern blood collection process can and should look like.”
YourBio Health is a Flagship Pioneering portfolio company. Both Dr Mina and Owen will join the Hims & Hers team following completion of the deal.
